Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of Psychosis

NCT00369239 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

303

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia
Psychotic Disorders
Schizoaffective Disorder

Interventions

DRUG: risperidone long acting injectable

Sponsor

Janssen Pharmaceutica N.V., Belgium